Barely Significant
← all excerpts

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.

Cancer Res Treat · 2022 · PMC9016311 · PMID 34352999

Europe PMCDOI
1
hedged sentence
0.6170
closest p · 12.3× alpha
0.6170
boldest claim

The sentences

did not reach statistical significancep=0.617not close (p > 0.1)
Although there was a trend indicating that the patients in afatinib group had longer PFS than the erlotinib group, it did not reach statistical significance (log-rank test, p=0.617).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.